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Aggressive treatment, including resection of both metastasis and primary tumor, has been studied for non-small cell lung cancer
patients with synchronous solitary brain metastasis. Involvement of mediastinal lymph nodes is considered a poor prognostic
factor and a contraindication to surgical resection of the primary lung tumor after treatment for brain metastasis. Here we present
the case of a patient who presented with a Stage IV T1N2M1 non-small cell lung cancer with synchronous solitary brain metastasis.
He is alive and without evidence of disease two years after aggressive, multimodality treatment that included craniotomy, whole-
brain radiation therapy, thoracic surgery, chemotherapy, and mediastinal radiation therapy.
Copyright © 2009 T. N. Showalter and A. Lin. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Introduction
Brain metastases aﬀect approximately 25% of patients with
non-small cell lung cancer (NSCLC). For the subset of
patients who present with a solitary brain metastasis (SBM),
in the absence of other sites of metastatic disease, aggressive
local therapy to the primary and metastasis is warranted
[1]. Craniotomy for tumor resection and stereotactic radio-
surgery (SRS) are widely accepted components of therapy for
patients with SBM from NSCLC [1–4]. Several retrospective
studies support the surgical resection of the primary tumor
for NSCLC patients who present with synchronous, solitary
brain metastasis [5–8]. In most series, patients with negative
lymph nodes have better outcomes than patients with node-
positive disease [6, 8–10]. In fact, the American College
of Chest Physicians (ACCP) guidelines consider mediasti-
nal lymph node involvement to be a contraindication to
resection of the primary tumor for NSCLC with SBM [1].
However, the current case report is presented as an example
of long-term survival after aggressive, multimodality therapy
for an NSCLC patient with synchronous SBM and N2 nodal
disease.
2. Case Presentation
A 52-year-old male presented to medical attention with
severe headaches. Magnetic resonance imaging (MRI)
revealed an enhancing, intra-axial mass in the left cere-
bellum, measuring 2.3 × 2.3 × 2.5 cm and accompanied
by surrounding edema (Figure 1(a)). A CT of the chest,
abdomen, and pelvis was performed, revealing a left upper
lobe lung mass with ipsilateral hilar and mediastinal lym-
phadenopathy. The suspected clinical diagnosis was lung
cancer with brain metastasis. He underwent a suboccipital
craniectomy for removal of the brain lesion. Postoperative
MRI demonstrated gross total resection of the brain metas-
tasis (Figure 1(b)). Pathology showed metastatic, poorly
diﬀerentiated adenocarcinoma, with immunohistochemical
findings consistent with a primary lung tumor (TTF-1
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Figure 1: Axial, T1-weighted, postcontrast MR images of the brain. (a) A 2.3× 2.3× 2.5 cm left cerebellar lesion occurred synchronous with
the diagnosis of a primary NSCLC. (b) The left cerebellar lesion was completely removed through a left suboccipital craniectomy. (c) No
residual enhancement is noted after WBRT. (d) There is no evidence of recurrent brain metastasis on MRI obtained 2 years after diagnosis.
and CK7 positive). Whole-brain radiation therapy (WBRT)
was administered postoperatively, consisting of 2.5Gy daily
fractions to 37.5Gy, delivered with opposed lateral portals.
He was evaluated in multidisciplinary lung clinic after
WBRT for discussion of further management of his NSCLC.
His past medical history was significant for only hyperc-
holesterolemia and history of a benign right flank mass that
was surgically removed in the remote past. He had a thirty-
pack-year history of smoking and chose to quit smoking
when diagnosed with NSCLC. On examination, his lungs
were clear to auscultation bilaterally. No focal neurologic
deficits were discovered on examination. His Karnofsky
Performance Status (KPS) was 100%, with an absence of any
adverse prognostic factors such as weight loss or laboratory
abnormalities.
Staging evaluation was completed with whole-body, 18-
fluoro-deoxyglucose (FDG)-positron emission tomography
(PET)/computed tomography (CT) imaging, which demon-
strated a hypermetabolic left upper lobe tumor and two
hypermetabolic foci in the left para-aortic and suprahilar
regions (Figures 2(a) and 2(b)). The FDG-PET/CT findings
suggested a T1 primary tumor with N2 nodal disease. Given
the absence of distant dissemination elsewhere, the control
of intracranial disease (Figure 1(c)), and the patient’s good
KPS, it was decided that aggressive, multimodality therapy
would be oﬀered for management of the intrathoracic
component of NSCLC. Video-assisted thorascopic surgery
was performed for wedge resection of the LUL primary
tumor and mediastinal lymph node sampling. Pathology
showed poorly diﬀerentiated NSCLC, measuring 1.6 cm in
greatest dimensions with negative resection margins. Two
of 5 mediastinal lymph nodes in level V were positive, and
0 of 1 nodes in level IX. He subsequently received 5 cycles
of platinum-based adjuvant chemotherapy. Repeat FDG-
PET/CT after thoracic surgery and chemotherapy showed
only mild hypermetabolic activity (maximum SUV of 1.65)
in the LUL region, but no evidence of mediastinal uptake.
Given the pathologic confirmation of N2 nodal disease in
the surgical specimen, he was oﬀered mediastinal RT in
an eﬀort to reduce the risk of regional nodal recurrence.
He received 1.8Gy daily fractions of RT to a total dose
of 50.4Gy to a target volume that encompassed the entire
mediastinum (both ipsilateral and contralateral mediastinal
nodal stations) and ipsilateral hilum.
Case Reports in Medicine 3
(a) (b)
(c) (d)
Figure 2: Coronal views of FDG-PET/CT scan obtained before (a)-(b) and after (c)-(d) treatment for primary NSCLC in patient with
synchronous SBM. At diagnosis, the patient demonstrated hypermetabolic activity in a primary LUL tumor with mediastinal (a) and hilar
(b)lymphadenopathy. Two years after treatment, including surgical resection, chemotherapy, and mediastinal RT, there is no evidence of
hypermetabolic activity at the prior sites of thoracic involvement (c)-(d).
Two years after completion of therapy, whole-body FDG-
PET/CT imaging (Figures 2(c) and 2(d) and brain MRI
(Figure 1(d)) have demonstrated no evidence of disease. The
patient is without significant late toxicity from his diagnosis
or treatment and has returned to work full time.
3. Discussion
This case serves as an example of the aggressive manage-
ment of oligometastasis, a proposed, clinically significant
disease state that exists between locoregional confinement
and widespread metastatic disease [11]. The oligometastatic
state may represent a window in which aggressive local
intervention to sites of gross disease can result in long-term
disease control. Multiple studies have demonstrated long-
term survival for some patients after complete resection
of brain, lung, or liver metastases [2, 3, 12–17]. While
many of these patients had what are typically thought of as
more “indolent” cancers (colorectal or breast), a subset of
stage IV NSCLC patients will present with oligometastatic
disease. Oh et al., in their study of 1284 patients with
stage IV oligometastatic NSCLC, found that survival is
influenced by the number of metastatic organ sites or the
volume of oligometastatic disease in the brain or lung [18].
Therefore, the role of aggressive multimodality therapy in
oligometastatic stage IV NSCLC warrants careful study and
thoughtful consideration in clinical practice.
The use of aggressive, local therapy for SBM is sup-
ported by prospective trials that demonstrate a benefit for
craniotomy or SRS for brain metastasis [3, 4]. While the
addition of WBRT after surgery or SRS may not influence
overall survival to a significant degree, it can improve
local control, as supported by evidence from a prospective,
randomized trial [19]. However, there are less data regarding
management for the primary tumor in NSCLC patients who
present with SBM. Retrospective studies have demonstrated
benefit for aggressive local therapy for the primary lung
tumor in this scenario [5–7, 20, 21]. Nodal status has
been reported to be an important prognostic factor for
NSCLC patients with SBM who receive aggressive treatment
[5–8, 22], and treatment guidelines have suggested that
NSCLC patients with involved mediastinal nodes are not
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to be considered for resection of the primary tumor [1].
However, the present case represents an instance of durable
tumor control for a patient with synchronous SBM and N2
nodal disease. The long-term survival of NSCLC patients
with mediastinal nodal disease and SBM has been reported
infrequently in the literature [2], but our patient seems to
have benefited from an aggressive approach.
The patient in the current report presented with an excel-
lent performance status and was agreeable to an aggressive,
multimodality treatment approach. Abrahams et al., in their
report of 70 patients with NSCLC, found that the patients
who benefited most from an aggressive treatment approach
were those with a KPS of 100% [23]. Performance status
was the most important prognostic factor in the Radiation
Therapy Oncology Group recursive partitioning analysis of
brain metastasis patients [24]. Given these considerations,
performance status should be a primary consideration when
considering aggressive treatment for patients with NSCLC
and SBM.
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